Scienture Holdings, Inc. SCNX 深 沪
已收盘 08-14 16:00:00 美东时间
0.459
-0.006
-1.29%
华盛通- 最 高0.4668
- 今 开0.45
- 成交量 2968.51万股
- 最 低 0.41
- 昨 收 0.465
- 总市值 1864.95万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 73.06%
- 52周最低 0.2382
- 委 比 17.70%
- 总股本 4063.08万
- 历史最高 164.50
- 量 比 4.22
- 振 幅 12.22%
- 历史最低 -5.81
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $343.639 tho...
08-14 20:23
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has successfully fulfilled its initial purchase orders to pharmaceutical wholesalers across the U.S. The rel...
08-12 19:46
Why WD-40 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of WD-40 Co (NASDAQ:WDFC) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results. The company reported quarterly earnings of $2.33 per share, which beat the analyst consensus estimate of $1.56 per share. The company reported quarterl...
07-10 16:45
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Scienture Holdings, Inc. (NASDAQ:SCNX) shares jumped 21.25% to $0.4046 in overnight trading at the time of writing, adding to a 0.48% Thursday surge. Naloxone Spray Nears Market Launch The stock move came after the New York-based comprehensive health services and pharmaceutical company announced bef...
07-10 16:27
EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July
5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO MarketU.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually,represents significant
06-09 19:45
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.22) by 63.64 percent. This is a 75.76 percent increase over losses of $(0.33) per share
05-16 06:12
SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor
Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatmentFinancing also drives early-
05-07 20:20
USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension
05-06 20:08
Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing
https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view
04-28 01:05
